[Insert Table 2]
On the other hand, seven studies were included to calculate pooled
relative risk for severe/critical disease [11,13,14,18-21] in
COVID-19 patients with hypertension, exposed or unexposed to ACEIs/ARBs
(Table 3 ). The studies from Feng et al. [15] and Peng et
al. [16] did not segregate the patients based on the presence of
hypertension and therefore were excluded from our pooled analysis to
ensure a uniform cohort of hypertensive patients being analysed.
Moreover, Lee et al. [12], Chen et al. [17], and Mehra et al.
[22] did not present data on severity by ACEIs/ARBs use and hence
were also excluded from the analysis.